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Abstract
Purpose: To examine whether ultra-widefield (UWF) retinal 
imaging can identify biomarkers for Alzheimer’s disease (AD) 
and its progression. Methods: Images were taken using a 
UWF scanning laser ophthalmoscope (Optos P200C AF) to 
determine phenotypic variations in 59 patients with AD and 
48 healthy controls at baseline (BL). All living participants 
were invited for a follow-up (FU) after 2 years and imaged 
again (if still able to participate). All participants had blood 
taken for genotyping at BL. Images were graded for the prev-
alence of age-related macular degeneration-like patholo-
gies and retinal vascular parameters. Comparison between 
AD patients and controls was made using the Student t test 
and the χ2 test. Results: Analysis at BL revealed a significant-
ly higher prevalence of a hard drusen phenotype in the pe-
riphery of AD patients (14/55; 25.4%) compared to controls 
(2/48; 4.2%) [χ2 = 9.9, df = 4, p = 0.04]. A markedly increased 
drusen number was observed at the 2-year FU in patients 
with AD compared to controls. There was a significant in-
crease in venular width gradient at BL (zone C: 8.425 × 10–3 
± 2.865 × 10–3 vs. 6.375 × 10–3 ± 1.532 × 10–3, p = 0.008; entire 
image: 8.235 × 10–3 ± 2.839 × 10–3 vs. 6.050 × 10–3 ± 1.414 × 
10–3, p = 0.004) and a significant decrease in arterial fractal 
dimension in AD at BL (entire image: 1.250 ± 0.086 vs. 1.304 
± 0.089, p = 0.049) with a trend for both at FU. Conclusions: 
UWF retinal imaging revealed a significant association be-
tween AD and peripheral hard drusen formation and chang-
es to the vasculature beyond the posterior pole, at BL and 
after clinical progression over 2 years, suggesting that mon-
itoring pathological changes in the peripheral retina might 
become a valuable tool in AD monitoring.
© 2018 S. Karger AG, Basel
Craig Ritchie, Tunde Peto, and Imre Lengyel are senior authors.
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Background 
Alzheimer’s disease (AD) is characterised by the for-
mation of extracellular amyloid beta (Aβ) plaques, the 
presence of intracellular neurofibrillary tangles in the 
brain [1], and altered levels of Aβ and Tau in the cerebro-
spinal fluid [2]. However, definite diagnosis still only pos-
sible at post-mortem examination of autopsy samples [3]. 
Diagnosing and monitoring the progression of AD in the 
brain with the currently available methods is invasive, in-
sensitive, and expensive, and often requires the use of ra-
dioactive isotopes [4, 5]. Therefore, there is an urgent 
need for methods that can noninvasively, cost-effectively, 
and safely identify individuals at risk of disease progres-
sion.
The retina is part of the central nervous system, origi-
nates from the developing diencephalon, and shares 
structural and functional features with the brain [6–8]. 
Therefore, examination of macular images was suggested 
as a monitoring tool for the changes in the brain [9, 10]. 
Changes in retinal morphology such as optic disc chang-
es [11–14], retinal nerve fiber layer thinning [14–16], and 
loss of retinal ganglion cells [17–20] might be associated 
with AD. A possible relationship between drusen forma-
tion in the macula and the severity of AD [21–24] has also 
been shown. Furthermore, due to the homology of the 
retinal and cerebral microvasculature, the condition of 
the retinal vasculature has been considered as a proxy for 
cerebral microvascular health [9]. Measuring geometric 
features of vessels visible on retinal imaging such as width 
and tortuosity is considered to infer the health of the ret-
inal microvasculature, which reflects the state of the cere-
bral microvasculature. Studies have reported vascular ab-
normalities in the retina from the analysis of fundus cam-
era images, including sparser arteriolar and venular 
networks and vessel caliber and tortuosity changes in the 
macula in AD, but with conflicting outcomes due to var-
ied protocol, small sample size, or variations in pheno-
types considered as AD [25].
The macula occupies only a small proportion of the 
retina, and significant changes do occur in the peripheral 
retina with age [26, 27] and disease [28–30]. Technologi-
cal advances brought about by the advent of the ultra-
widefield scanning laser ophthalmoscope (UWF-SLO) 
now allow identification of peripheral retina abnormali-
ties [27], similar to what can be observed in the macula 
[1], including retinal vascular parameters (RVPs) [31]. In 
fact, peripheral retina abnormalities do not need to di-
rectly correlate with changes in the macula; for example, 
drusen deposits within the peripheral retina have been 
observed in eyes with no macular deposits present [26, 
27]. Here we investigated whether associations exist be-
tween retinal periphery changes and AD using UWF im-
aging, and we report, for the first time, retinal character-
istics that might become candidate biomarkers for AD 
and its progression.
Methods
Ethics approval for the study protocol was obtained from the 
Ealing and West London Mental Health Trust Research Ethics 
Committee. The study complied with the Helsinki Declaration. 
Data collection took place at the West London Cognitive Disor-
ders Treatment and Research Unit (WLCDTRU). Altogether, 59 
patients and 48 controls entered this study. The controls were 
drawn from carers of index patients. Two patients had their data 
excluded from analysis due to suspected diagnosis of Lewy Body 
disease instead of AD based on the NINCDS-ADRDA criteria [32]. 
One patient’s images were not gradable due to an inability to com-
ply, giving a final analysis set of 56 AD and 48 controls at baseline 
(BL), and 16 AD and 16 controls at follow-up (FU). Medical his-
tory and standard socio-demographic factors such as age, gender, 
and education level were collected, as these may confound the re-
lationship between AD and the presence of drusen. All study par-
ticipants had blood drawn for the determination of genotype.
Image Grading for Age-Related Macular Degeneration-Like 
Pathology
Participants were imaged using the Optomap P200C UWF-
SLO (Optos Plc, Dunfermline, UK) operated by an imaging team 
from Optos, consisting of an imaging expert who was supervised 
by a clinician (T.P.) from the Moorfields Eye Hospital Reading 
Centre (MEHRC). The P200C uses red (633 nm) and green (532 
nm) lasers which are reflected off a large concave elliptical mirror 
to direct them to regions of the back of the eye that are inaccessible 
with other methods of fundus imaging. This instrument stores im-
ages in tiff format with dimensions 3,900 × 3,072 pixels.
Image grading was carried out by certified MEHRC graders 
masked to the participants’ case-control status. Images were grad-
ed in random order without access to clinical information using 
the Optos V2 Vantage Dx Review 2.5.0.135 software that places a 
grading grid on an UWF image. This grid is based on the original 
definition of a standard macular grid defined by the distance be-
tween the centres of the optic nerve head and the fovea [33]; ex-
tended by 2 further zones, i.e., zone 4 for the mid-periphery, and 
zone 5 for the far periphery. Drusen size was measured using es-
tablished standard measuring tools and lesion sizes [33] on unpro-
jected images. Only abnormalities resembling age-related patholo-
gies such as hard and soft drusen, retinal pigment epithelial chang-
es, pigment epithelial detachment, geographic atrophy, and 
choroidal neovascularisations were graded [33]. 
We previously reported that UWF images were gradable in the 
macula, even on images that fell short of grading standards on con-
ventional fundus images [27]. This was due to the SLO instrument 
being less susceptible to media opacities than conventional fundus 
imaging. Occasionally, grading on > 1 image had to be carried out 
from the same eye, due to blinking during acquisition (which ob-
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scures parts of the retina) or artefacts caused by an individual ex-
periencing difficulty in opening their eyelids. The study was 
planned to be conducted without mydriasis, with the option for 
using dilation with tropicamide 1% (Alcon) if needed. Interest-
ingly, dilation was necessary in all AD patients to enable good-
quality retinal photographs to be taken, while only 7 of the controls 
required dilation.
Analysis was undertaken in SPSS (Rel. 14.0.0. 2007; SPSS Inc., 
Chicago, IL, USA). An association between AD status and the pres-
ence of drusen in 4 states/locations was investigated using the χ2 
test. Exploration of potential confounders (i.e., clinical, genetic, 
and sociodemographic) was undertaken and adjusted following 
nominal regression analysis, given the categorical nature of the 
exposure and outcomes. Potential confounders were selected for 
regression analysis if their association with both the exposure and 
principal outcome generated a p value of < 0.1. 
Image Analysis for RVPs 
Prior to the measurement of RVPs, the UWF images were as-
sessed by a trained operator who judged each image in terms of the 
available area of retina imaged and the contrast between the visible 
vasculature and retinal background. Eyelashes can sometimes ob-
scure large parts of the retina, preventing RVP measurements. 
Poor image contrast, resulting from difficulties with the acquisi-
tion (e.g., inexact participant positioning), means the computa-
tional analysis of vessels is sometimes not achievable. After assess-
ment, images deemed acceptable for analysis were stereographi-
cally projected, to compensate for distortions due to the retinal 
curvature and to enable the subsequent measurements made on 
the images in pixels to be converted to millimetre equivalents on 
the retina [34]. The operator then identified the region of interest 
in each image by masking out shadows caused by any eyelashes and 
areas of low contrast at the image edges, before enacting automat-
ic segmentation of the vasculature [31]. Manual refinement re-
moved artefacts (i.e., spurious vessel detections) and separated out 
the arteriolar and venular components of the vascular tree by label-
ling vessels and marking crossing points by hand. 
For RVP analysis, we placed the conventional set of circular 
measurement zones commonly used for fundus camera imaging on 
the projected UWF images [25]. This was zone B, which is a ring 
0.5–1 OD in diameter away from the centre of the OD, and zone C, 
which is a ring extending from the OD boundary to a 2-OD diam-
eter away (Fig. 1). We also performed novel analysis that is only 
possible with UWF imaging by utilising the whole area of the visible 
retina permitted by each image, from the OD boundary out towards 
the periphery. RVPs were measured in these zones using software 
specially designed to handle UWF imaging, VAMPIRE for UWF-
SLO (v1, Universities of Edinburgh and Dundee, UK), and were in 
agreement with previously reported analysis of fundus camera im-
aging [35], except for the novel parameters described below. 
Fig. 1. Grading of vascular parameters on 
UWF imaging. Dashed circles represent 
grading zones B: 0.5–1 OD diameter. C: 
1–2 OD diameter. Turquoise lines, vascu-
lar fractal dimension; green dots, branch-
ing points; red line, arteriole; blue line, ven-
ule.
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Novel Parameters
The tortuosity of arterioles and venules (TORTa and TORTv, 
respectively) were measured [36] for the large vessels originating 
in zone B identified visually by the operator, who selected the path 
followed by these vessels into zone C or as far as the image permit-
ted towards the periphery (entire image). Tortuosity measure-
ments per quadrant were collected, using 2 segregating lines to 
divide the retina, one through the centre of the OD and fovea, and 
the second perpendicular to the first and through the OD. The pa-
rameters recorded included “main,” which corresponded to the 
tortuosity of the principal path of the main vessel, and “total,” 
which involved calculating the median tortuosity for all the vessel 
segments that were measured. 
Further analysis of the main vessels (1 arteriole and 1 venule 
per quadrant, as selected by the operator) was conducted by mea-
suring vessel calibre at regular intervals (every 4 pixels) along the 
entire vessel path (Fig. 2a). Quantifying how the width diminishes 
as the vessel extends out towards the periphery was achieved by 
fitting a straight line to the calibre measurements (Fig. 2b). The 
gradient of the straight-line fit for the main vessels gives the width 
gradient (WG), i.e., arterial WG (WGa) and venular WG (WGv), 
respectively. An abnormal decline in vessel width as reflected in 
the evaluation of WG may indicate irregular vessel health.
Results
Genotyping and Background Factors
The following factors were associated with AD: ApoE4 
RS429358 status (χ2 = 4.9, df = 2, p = 0.09), a history of 
transient ischemic attack (TIA; χ2 = 3.1, df = 1, p = 0.08), 
and being an ex-smoker (χ2 = 5.6, df = 2, p = 0.06). Patients 
with AD were slightly older (79.2 [SD 8.4] years) than con-
trols (70.7 [SD 10.4] years) (p < 0.0001). Peripheral retinal 
clinical findings were associated with a history of heart 
failure (χ2 = 8.1, df = 4, p = 0.09), stroke (χ2 = 10.1, df = 4, 
p = 0.04), and TIA (χ2 = 8.1, df = 4, p = 0.09). Given the 
strength of the association between age and dementia, and 
the co-occurrence of TIA history with both dementia sta-
tus and retinal changes, the phenotyping model was re-
analyzed, taking these variables into account. This adjust-
ed analysis demonstrated a very strong association be-
tween variability on peripheral clinical findings and AD 
(likelihood ratio test, χ2 = 32.3, df = 12, p = 0.001).
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Fig. 2. Determination of vascular gradient. a Turquoise line shows an identified venule. b Blue circles are measured vascular width; tur-
quoise line depicts best fit.
D
ow
nl
oa
de
d 
by
: 
Ic
el
an
d 
Co
ns
or
tiu
m
 - 
Vo
da
fo
ne
 Ic
el
an
d 
   
   
   
   
   
  
89
.1
60
.2
11
.1
93
 - 
4/
8/
20
18
 9
:3
3:
14
 A
M
Peripheral Retinal Imaging Biomarkers 
for Alzheimer’s Disease: A Pilot Study
5Ophthalmic Res
DOI: 10.1159/000487053
Image Grading for Age-Related Macular 
Degeneration-Like Pathology 
On grading for age-related macular degeneration 
(AMD)-like lesions, the AD patient group showed an in-
creased incidence of AMD compared to controls (4 vs. 1, 
respectively), but significance could not be calculated giv-
en the small numbers in each group.
Next, we determined the clinical phenotype of the pe-
ripheral retina changes. We applied a hierarchical pheno-
typing protocol: those with hard drusen only were as-
signed to the hard drusen phenotype. Those with both 
hard and soft drusen were designated as the soft drusen 
phenotype. Eyes were phenotyped as atrophy even if they 
had hard or soft drusen or pigment changes. Based on this 
phenotyping, AD patients were significantly more likely 
to be phenotyped as hard drusen in the periphery (14/55 
[25.4%] of AD patients vs. 2/48 [4.2%] of controls; χ2 = 
9.9, df = 4, p = 0.04). No significant differences could be 
found in the soft drusen, pigment changes, and atrophy 
phenotypes (Fig. 3). 
50
40
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Normal Hard drusen Soft drusen GA Ungradable
Control
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Peripheral grading result
Fig. 3. Hierarchical phenotyping for AMD-
like pathologies in AD. AD patients were 
significantly more likely to be phenotyped 
as hard drusen in the periphery compared 
to controls (14/55 [25.4%] vs. 2/48 [4.2%]; 
χ2 = 9.9, df = 4). * p = 0.04. 
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Fig. 4. Zone-specific grading for AMD-like pathologies. Red, an increased AD prevalence; white, no difference; pink, intermediate dif-
ference. SN, superior nasal; IN, inferior nasal; IT, inferior temporal; ST, superior temporal; RPE, retinal pigment epithelium; Hyper AF, 
Hyper-autofluorescence; Hypo AF, Hypo-autofluorescence; PED, pigment epithelial detachment; CNV, choroidal neovascularization. 
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a b
c d
e
f
Fig. 5. Representative colour (a, b) and corre-
sponding autofluorescence (AF) (c, d) images at 
the peripheral retina for progression in an AD 
eye that occurred during the 2 years till follow-
up. a, c At baseline. b, d At follow-up. Black ar-
rowheads denote progression. e, f UWF images 
representative of AF progression. Arrows, pro-
gression to atrophy; arrowheads, progression to 
hyper-AF.
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Grid-specific appearance of different pathological 
signs were also plotted based on our previous analysis 
[27]. Due to the difficulty for the patients to open their 
eyelids wide, and therefore our inability to generate good 
quality images in zone 5, we only analyzed zones 1–4. 
Then we subtracted the incidences of the appearance of 
phenotypic features of AD patients from those at the 
same geographic location in controls, and plotted these 
differences in Figure 4 (those with a higher prevalence in 
AD were labelled red, white indicates no difference, and 
pink an intermediate small difference). This semi-quan-
titative assessment highlighted that, in AD, most of the 
increased incidences of pathological changes were associ-
ated with the superior and/or nasal part of the retina 
(Fig. 4). 
At FU, only 16 AD and 16 controls could participate, 
and therefore we could only make a qualitative assess-
ment of their drusen load. There were a few more visible 
drusen detected in controls at the 2-year FU; however, in 
the AD eyes, the increase in drusen numbers was consis-
tently higher than in controls (Fig. 5). 
RVP Measurements
Of the 32 participants with a FU, 27 participants (13 
AD patients and 14 controls) could be analyzed at BL, and 
23 (9 AD and 14 controls) at FU. Analyzing zone B (Fig. 1) 
revealed no significant differences between controls and 
AD at BL or at FU, and no progression (a comparison of 
BL with FU) could be detected (results not shown). 
Analyzing zone C (Fig.  1) revealed increases in the 
WGv when the AD group was compared to controls at BL 
(8.42 × 10–3 ± 2.80 × 10–3 and 6.37 × 10–3 ± 1.53 × 10–3, 
respectively; p = 0.008). This appeared to be driven by the 
increase in WGv in the superior nasal quadrant (10.73 × 
10–3 ± 7.68 × 10–3 and 5.00 × 10–3 ± 2.86 × 10–3, respec-
tively; p = 0.005) (Table 1). In contrast, there were no dif-
ferences in WGa at BL, but there was a significant de-
crease in WGa in the superior temporal quadrant in AD 
Table 1. Comparison of width gradient values in AD cases and controls
Parameter AD cases
(n = 13)
Controls
(n = 14)
p AD cases
(n = 9)
Controls
(n = 14)
p
at BL at BL at FU at FU
Zone C 
WGa-ST 4.850 (3.358) 5.378 (3.107) 0.605 3.292 (1.872) 5.355 (2.617) 0.022
WGa-IT 5.325 (5.534) 4.030 (2.193) 0.336 6.608 (6.322) 4.814 (4.171) 0.333
WGa-IN 8.800 (8.156) 6.138 (5.489) 0.226 10.445 (8.021) 6.482 (8.150) 0.195
WGa-SN 5.958 (4.249) 4.847 (3.450) 0.382 4.483 (4.044) 3.294 (2.871) 0.362
WGa-all 6.170 (3.099) 5.013 (2.151) 0.152 6.175 (2.549) 5.410 (2.531) 0.411
WGv-ST 7.495 (3.310) 6.708 (3.852) 0.477 6.433 (1.836) 6.323 (3.035) 0.909
WGv-IT 7.395 (3.947) 6.174 (1.589) 0.180 11.033 (11.547) 6.181 (2.740) 0.178
WGv-IN 8.542 (3.968) 7.465 (3.282) 0.341 11.255 (6.140) 7.836 (4.607) 0.082
WGv-SN 10.730 (7.677) 5.004 (2.865) 0.005 8.055 (8.005) 5.305 (2.495) 0.290
WGv-all 8.425 (2.865) 6.375 (1.532) 0.008 9.275 (4.999) 6.400 (1.728) 0.077
Entire image
WGa-ST 4.358 (3.302) 5.322 (3.100) 0.336 3.133 (1.583) 4.991 (2.639) 0.015
WGa-IT 5.135 (5.179) 3.809 (2.234) 0.298 6.542 (6.290) 4.319 (3.486) 0.199
WGa-IN 8.430 (7.698) 5.714 (4.795) 0.181 10.327 (7.816) 7.505 (6.487) 0.284
WGa-SN 5.605 (5.605) 4.884 (3.562) 0.571 4.333 (4.041) 2.978 (2.964) 0.298
WGa-all 5.835 (2.976) 4.970 (1.948) 0.275 6.017 (2.571) 5.124 (2.368) 0.320
WGv-ST 7.300 (4.031) 6.533 (3.143) 0.471 6.358 (1.800) 6.245 (3.091) 0.909
WGv-IT 7.240 (3.939) 5.888 (1.713) 0.136 11.000 (11.564) 6.000 (2.796) 0.167
WGv-IN 8.384 (4.031) 7.091 (3.085) 0.246 10.773 (6.187) 7.464 (4.534) 0.090
WGv-SN 10.495 (7.707) 4.796 (2.769) 0.006 7.664 (7.814) 5.129 (2.412) 0.316
WGv-all 8.235 (2.839) 6.050 (1.414) 0.004 8.992 (4.833) 6.264 (1.695) 0.082
The values are mean (SD). Bold type denotes significant differences. p values were calculated by independent 
t test. AD, Alzheimer’s disease; BL, baseline; FU, follow-up; WGa, arterial width gradient; WGv, venular width 
gradient; all, all quadrants; ST, superior temporal quadrant; IT, inferior temporal quadrant; IN, inferior nasal 
quadrant; SN, superior nasal quadrant. 
D
ow
nl
oa
de
d 
by
: 
Ic
el
an
d 
Co
ns
or
tiu
m
 - 
Vo
da
fo
ne
 Ic
el
an
d 
   
   
   
   
   
  
89
.1
60
.2
11
.1
93
 - 
4/
8/
20
18
 9
:3
3:
14
 A
M
Csincsik et al.Ophthalmic Res8
DOI: 10.1159/000487053
patients versus controls at FU (3.29 × 10–3 ± 1.87 × 10–3 
vs. 5.35 × 10–3 ± 2.61 × 10–3 respectively; p = 0.022) (Table 
1). Despite these changes, no statistically significant pro-
gression could be detected in zone C (data not shown), 
possibly due to the small numbers.
The most consistent differences between AD patients 
and controls were observed when the entire image was 
considered; we detected a significant difference in arte-
rial fractal dimension (FDa) at BL (1.25 ± 0.08 and 1.30 ± 
0.09 respectively; p = 0.049) with a trend at FU (p = 0.092) 
(Table 2). In addition, the observed significant increase in 
WGv in zone C remained significantly higher in AD pa-
tients compared to controls when all quadrants were con-
sidered (8.23 × 10–3 ± 2.84 × 10–3 vs. 6.05 × 10–3 ± 1.41 × 
10–3; p = 0.004). This difference was most likely driven by 
the significant increase in WGv in the superior nasal 
quadrant (10.49 × 10–3 ± 7.70 × 10–3 vs. 4.79 × 10–3 ± 2.77 
× 10–3; p = 0.006). The significant decrease in WGa in AD 
patients in zone C in the superior temporal quadrant re-
mained when the entire image was analyzed (3.13 × 10–3 
± 1.58 × 10–3 vs. 4.99 × 10–3 ± 2.63 × 10–3; p = 0.015) (Ta-
ble 1). As for zone C, no statistically significant progres-
sion could be detected in RVPs on the whole image (data 
not shown).
Discussion
Previous studies that examined retinal pathologies in 
AD concentrated on the macula and investigated the po-
tential associations between AMD and AD. Using fundus 
camera images, several of these studies suggested that the 
2 diseases share some pathomechanisms as well as envi-
ronmental and genetic risk factors [21, 37–39]. However, 
such associations are still being debated [40]. The macula 
is only a small portion of the retina, and AMD-like pa-
thologies are widespread at the peripheral retina, even in 
the absence of macular changes, so we examined the en-
tire retina of patients with AD. We analyzed the UWF 
images for AMD-like pathologies as well as retinal vascu-
lar changes, and compared these to controls with no his-
tory of dementia. Our results indicate that analyzing the 
peripheral retina could yield potential biomarkers for AD 
and its progression, both in drusen deposition and in vas-
cular characteristics. 
In the peripheral retina, hard drusen accumulation, es-
pecially in the superior nasal quadrant, was significantly 
associated with positive AD status (p = 0.04) at BL image 
grading. When results were adjusted for age and a history 
of TIA, the association between the peripheral hard dru-
sen phenotype and AD increased in significance (p = 
0.001). At the 2-year FU examination conducted on those 
who were still able to comply, we found that there were 
more areas associated with drusen deposition in AD but 
we also observed a consistently higher increase in drusen 
numbers in all patients when compared to controls. The 
increase in drusen number in the control group was ex-
pected with the advancement of age [41]. 
In addition to peripheral hard drusen accumulation, 
changes in some of the RVPs were also associated with 
AD in our study. We were able to extend the vascular 
analysis beyond the B and C zones conventionally em-
ployed for standard fundus camera imaging. We ana-
lyzed, for the first time, the entire visible image area ob-
tained with UWF-SLO. Previous studies investigating 
zones B and C on conventional fundus camera images 
Table 2. Comparison of fractal dimension values in AD cases and controls
Parameter AD cases
(n = 13)
Controls
(n = 14)
p AD cases
(n = 9)
Controls
(n = 14)
p
at BL at BL at FU at FU
Zone C
FDa 1.166 (0.063) 1.197 (0.061) 0.112 1.170 (0.051) 1.194 (0.062) 0.254
FDv 1.190 (0.066) 1.191 (0.057) 0.968 1.190 (0.069) 1.179 (0.066) 0.666
Entire image
FDa 1.250 (0.086) 1.304 (0.089) 0.049 1.262 (0.064) 1.311 (0.085) 0.092
FDv 1.307 (0.081) 1.323 (0.065) 0.479 1.310 (0.081) 1.329 (0.069) 0.469
The values are mean (SD). Bold type denotes significant differences. p values were calculated by independent 
t test. AD, Alzheimer’s disease; BL, baseline; FU, follow-up; FDa, arteriolar fractal dimension; FDv, venular fractal 
dimension.
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found several significant differences in RVPs in zone B 
[10, 35, 42]. While we measured comparable RVPs (Table 
1) from the UWF imaging, we did not detect such differ-
ences in AD patients and controls. In zone C, based on 
the previous reports, the most consistent RVP outcome 
was a decrease in retinal fractal dimensions in AD [10, 35, 
42]. We did not find evidence of changes in FD in zone C 
from our measurements. The lack of observed effect in 
previous studies could have been due to the use of pa-
tients with more advanced AD, but possibly also due to 
the lower resolution in UWF images than in fundus color 
images (i.e., 10–15 vs. approx. 7 µm). A direct comparison 
of these imaging modalities would help clarify this issue 
in the future. Despite the lack of measurable FD differ-
ences in zone C, we found a decreased FDa when the anal-
ysis was extended to the entire image, i.e., encompassing 
the peripheral retina (Table 2). Recent studies correlated 
retinal FD with cerebral cortical volumes and found a 
positive correlation with FDa [43]. As decreased cortical 
volume has been associated with AD [44–46], changes in 
FDa in the peripheral retina might be a new prospective 
biomarker and a surrogate for AD-associated atrophy.
There are conflicting outcomes in the literature for ret-
inal vascular tortuosity measured in zone C. Frost et al. 
[35] reported decreased TORTv but no change in 
TORTa. Cheung et al. [10] found increased TORTa and 
TORTv. Williams et al. [42] detected a decrease in 
TORTa only. From our measurements, we did not find 
evidence of any differences in tortuosity between AD and 
control in zone C, nor did we find a difference when the 
entire image was considered. This inconsistency of the 
studies is likely due to the different algorithms used for 
calculating tortuosity and the number of samples used to 
construct the final summative parameter. Whether tortu-
osity is a possible surrogate for AD therefore remains 
questionable, as a protocol for measuring this parameter 
is yet to be optimized.
Vascular WG measurement is a novel parameter to as-
sess changes in the retinal vasculature. For this measure-
ment, we analyzed the main vessels over a longer path 
distance than is achievable with standard fundus camera 
imaging. As WG indicates how the diameter of a vessel 
thins from the more central to the peripheral areas, it 
might be directly proportional to blood flow. We found 
that there is a significant increase in WGv in AD. Given 
that we did not find significant differences in vascular cal-
ibres in zone B between the AD and control groups, the 
increased WGv in zone C and beyond indicates a more 
pronounced thinning of venules towards to the periph-
eral retina. The result of this thinning is likely to be a de-
creased blood flow in AD. Taken together, the increased 
WGv and lower FDa represent a less complex and spars-
er vascular bed, leading to decreased oxygenation and 
availability of nutrients as well as sub-optimal clearance 
in the peripheral retina. The thinner veins and a less com-
plex arterial network may generate an environment that 
is more conducive to degeneration, and might even be 
related to the increased drusen accumulation and pro-
gression we have observed in AD. It would be interesting 
to study whether WGs in the brain vasculature correlate 
with increased plaque deposition in AD.
One of the major limitations of all AD studies on the 
eye is the small number of participants enrolled [25]. Al-
though the sample size in our study was modest, a geno-
typic association between AD and the ApoE4 RS429358 
allele type was demonstrated, suggesting that the selection 
process was representative of AD [47]. As in previous 
studies [21, 22], we observed a potential association be-
tween AD and AMD based on the appearance of end-stage 
AMD in the macula. However, we believe that the small 
sample size does not allow this produce a statistically 
meaningful conclusion. Another limitation was that we 
conducted multiple testing for associations with different 
types of eye pathology, which may have led to a type 1 er-
ror, and the relatively small sample size to a type 2 error. 
In addition, although the controls were deemed to not 
have AD according to the NINCDS-ADRDA criteria, we 
cannot rule out that they could have had pre-clinical AD.
In conclusion, based on the data we presented in this 
paper, we are promoting the possibility that increased pe-
ripheral hard drusen deposition, decreased FDa, and in-
creased WGv are potential imaging-derived biomarkers 
of AD. To be a reasonable marker of early disease, pre-
symptomatic people or early symptomatic (pre-demen-
tia) patients would need to be followed up over several 
years to determine the predictive value of the peripheral 
retina findings with regard to the development of demen-
tia. Moreover, associations with other putative markers of 
AD would be illuminating rather than relying solely on 
associations with the prominent clinical phenotype of 
AD. Prospective studies with a greater number of patients 
and earlier disease stages (e.g., the Deep and Frequent 
Phenotyping Study [48] and the PREVENT Dementia 
Cohort [49]) will help elucidate whether this can be veri-
fied in a larger cohort. If the observations made in this 
initial study remain robust, then routine UWF imaging 
might achieve an earlier and thereby clinically opportune 
and cost-effective method for monitoring the progression 
of AD and identifying individuals at a high risk of devel-
oping AD. 
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